RadNet Touches New 52-Week High

Shares of RadNet Inc. (RDNT) hit a new 52-week high of $3.97 in mid-day trading on Apr 7 eventually closing at $3.76 on the same day. In fact, shares of this CA-based outpatient diagnostic imaging services provider have been gaining momentum since it reported strong fourth-quarter and full-year 2013 results on Mar 3.

Year to date, the company's shares recorded a healthy return of 132.1%. The company's long-term estimated EPS growth rate is pegged at 10%.

Strong First-Quarter Performance

RadNet posted stronger-than-expected fourth-quarter results. The company's adjusted earnings per share (excluding severance costs, loss of disposal and amortization of deferred financing fees and discount on issuance of debt) were 9 cents in the quarter, which beat the Zacks Consensus Estimate by 8 cents and increased significantly from the prior-year quarter's loss of 11 cents per share.

RadNet's fourth-quarter revenues increased 11.9% year over year to $178.3 million, beating the Zacks Consensus Estimate by 3.12%. For full-year 2013, the company's revenues were $703 million, up 8.6% from 2012.

In the fourth quarter, RadNet performed an increased number of total procedures which came in at 1,137,825, up 12.2% from the prior-year quarter; with major hikes in procedures for MRIs and routine imaging exams.

For the fourth quarter of 2013, Radnet's MRI volume increased 16.8% while CT volume increased 5% over the prior-year quarter. The company's overall volume, including x-ray, ultrasound, mammography and other exams, increased 12.2% in the quarter and 9.3% in 2013.

Sequentially, RadNet experienced significant improvement in its operating performance, primarily driven by increased revenues and procedures as well as solid expense management.

Other Stocks to Consider

RadNet currently carries a Zacks Rank #4 (Sell). Some stocks that warrant a look within the broader medical sector are Alkermes plc (ALKS), Alexion Pharmaceuticals, Inc. (ALXN) and ANI Pharmaceuticals, Inc. (ANIP). All these stocks carry a Zacks Rank #1 (Strong Buy).

Read the Full Research Report on RDNT
Read the Full Research Report on ANIP
Read the Full Research Report on ALXN
Read the Full Research Report on ALKS


Zacks Investment Research